Fibrocell Science Inc. (FCSC) won U.S. approval for an injectible wrinkle treatment that uses a patient’s own stem cells to restore elasticity to the skin. The Food and Drug Administration cleared azficel-T, the company said today in a statement. Fibrocell plans to sell the drug under the name LaViv. Shannon Pettypiece reports on Bloomberg Television’s “Fast Forward.” (Source: Bloomberg)
See Fibrocell Science Website for more information.